INTRODUCTION
Glial cells of the retina, as in other parts of the CNS, often proliferate in response to pathological conditions such as ischemia and trauma. The proliferation of glia may be a significant factor in compromising neural function with disease or injury. For example, glial proliferation in the eye appears to be an important cellular event associated with reduced neuronal function caused by detachment of the retina from the underlying retinal pigment epithelium ~.
Although glial mitogenesis is likely to play a significant role in retinal pathobiology, knowledge concerning the regulation of the proliferative response of retinal glia is limited. In this study we asked whether glutamate, a neurotransmitter for the photoreceptors and bipolar cells 21, may serve as a mitogen for human retinal glial cells. Glutamate was chosen for study because the extracellular concentration of this transmitter increases in the nervous system under various pathophysiological conditions 8't6 that can be associated 20 34 with glial proliferation ' . Direct effects of glutamate on glia appear to be possible, since various types of glial cells have glutamate receptors 6.
To detect a possible proliferative effect of glutamate, we used cultures of glial cells derived from the adult human retina. An advantage of a cell culture system was the ability to quantify a mitogenic effect on human retinal glial cells of glutamate and various of its agonists and antagonists under serum-free conditions in the absence of significant numbers of non-glial ceils. We report that glutamate can stimulate significantly the proliferation of human retinal glial cells in culture. Pharmacological experiments indicate that activation of NMDA (N-methyl-D-aspartate) receptors plays a role in the mitogenic response of the gliai cells to glutamate. These findings support the hypothesis that a sustained elevation of glutamate may serve as a signal for the proliferation of glial cells in the retina.
MATERIALS AND METHODS

Cell culture
Cultures of retinal glial cells were prepared using modifications 28'3° of methods developed by others 2'25. Postmortem eyes from donors aged 39-87 years were supplied within 24 h of death by the Michigan Eye Bank. Retinas were removed, exposed to a calciumand magnesium-free phosphate buffer (CMF) supplemented with 0.1% trypsin (3×crystallized; Worthington), 0.2% hyaluronidase (Sigma) and 4% chicken serum (GIBCO) for 45 min at 37°C and then dissociated mechanically in 80% medium A 20% fetal bovine serum. Dissociated cells from one retina were added to three 35-mm Petri dishes, kept in a humidified environment of 96.5% air/3.5% CO2, at 37°C and fed with 80% medium A and 20% fetal bovine serum twice per week. Cultures that reached more than 80% confluency were split to three 35-mm Petri dishes. Cells that had been in culture for 2-6 passages were used. Cultures of retinal glial cells from 11 donors were assayed; all were sensitive to NMDA.
As reported elsewhere 3°, virtually all of the cells prepared by this method are immunoreactive to a monoclonal antibody specific for retinal Miiller cells. Also, the cells in this culture system stain positively with antibodies to glial fibrillary acidic protein 3°, as do Miiller glia and astrocytes in the human retina 36. Fig. 1 shows that the cells in our culture stain positively with polyclonal antibodies against glutamine synthetase. Immunoreactivity for glutamine synthetase is localized in the retina in situ to the Miiller glial cells and does not occur in the astrocytes located on the inner surface of the retina 19. Thus, immunocytochemical markers indicate that the cells in these cultures are Miiller cells.
Cell proliferation assays
Changes in cell number and incorporation of bromodeoxyuridine (BrdU) into glial nuclei were as detailed previously 29'3°'3s. In brief, retinal glial cells from a near confluent culture were removed from the dish by exposure for 15 min to 0.1% trypsin in CMF, centrifuged and resuspended in 7 ml of 80% medium A and 20% fetal bovine serum. Aliquots (0.15 ml) of the cell suspension were placed on 8x8-mm grids that had been imprinted on the bottoms of 35-mm plastic Petri dishes. The grids, which were imprinted using a template (Mecanex), contained a 26 × 26 array of alphabetically labeled squares. The day following addition of the 0.15 ml suspension of cells, 1.5 ml of 80% medium A and 20% fetal bovine serum was added to each dish. On the second day after the initial plating, a baseline cell count was performed for each Petri dish by starting at one corner of the grid and proceeding systemically until at least 100 cells had been counted. Recording the label of the first and last squares of the grid counter permitted recounting of the same area later. After baseline counting, the Petri dishes were washed twice with Dulbecco's modified Eagle's medium and exposed to medium B (medium A plus 50 ug/ml transferrin and 30 nM sodium selenite) supplemented as needed with various concentrations of L-glutamate (Sigma), NMDA (Sigma), kainate (KA; Sigma), quisqualate (QA; Research Biochemicals, Inc. (RBI)), D-2-amino-5-phosphonovalerate (D-AP5; Sigma), (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine hydrogen maleate (MK-801; RBI) and/or 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; RBI) for 2 days in initial experiments (Fig. 3) , for variable times (Fig. 4) or for 6 h (Figs. 5-9 ). Medium B contains 43 p,M glutamate and 250/xM glycine.
In some experiments (Table II) , medium C or one of its variations (Table I ) with or without 500 /zM NMDA was exposed to the cultures for 4.5 h. In experiments in which the exposure to glutamate agonists and/or antagonists was < 2 days, the cultures were switched to medium B. Two days after the initial cell counting, cells again were counted over the same areas of the grids as were surveyed for the baseline counts. The percent increase in cell number was then calculated.
In experiments examining the incorporation of BrdU into DNA, cells on grid-stamped dishes were exposed for 2 days to 10 p.M BrdU in medium B with or without the addition of 1 mM glutamate or 500 /.LM NMDA. BrdU was localized by immunocytochemical methods similar to those used by Yong et al. 37 , except the avidin-biotin-peroxidase method was used here. In brief, cultures were rinsed, then fixed with 70% ethanol at -20°C for 30 rain, exposed to 2 M HCI for 10 min to denature the DNA, bathed in 0.1 M sodium borate (pH 9) showed minimal label present in the cells. Scale bar represents 100/xm. for 10 min and then exposed to a monoclonal antibody to BrdU (1:10; Becton Dickinson) for 30 min at 37°C. Subsequently, the cultures were incubated in biotinylated anti-mouse IgG antibody (1:1,000: Vector) for 30 min at room temperature, followed by application of the avidin-biotin-peroxidase complex (1 : 100; Vector) with development in diaminobenzidine. Anti-BrdU staining is illustrated in Fig. 2 .
lmmunocytochemistry
Cultures were rinsed in phosphate-buffered saline (PBS), then fixed with 70% ethanol at -20°C for 30 rain. Cells were permeabilized with 0.5% Triton X-100 in PBS for 5 min. After washing with PBS, the cultures were exposed to 10% goat serum for 10 rain, then to a 1:100 dilution in PBS of rabbit anti-chicken glutamine synthetasc (a gift from Paul Linser) or control rabbit serum. After washing, the cultures were incubated with biotinylated goat anti-rabbit IgG (Vector) for 1 h, washed and then exposed for 45 min to an avidin and biotinylated horseradish peroxidase complex. The cultures were developed in diaminobenzidine. Fig. 3 shows the effect of various concentrations of glutamate on the proliferation of human retinal glial ceils in culture. A concentration-dependent increase in the number of retinal glial cells occurred under serum-free conditions. The increases in cell number at concentrations > 100 /zM were significant (P < 0.05, Student's t-test). The half-maximally effective concentration of glutamate was 280/zM. A maximal stimulatory effect occurred with 1 mM glutamate. Concentrations of glutamate greater than 1 mM were toxic to the glial cells.
l
Mitogenic response of retinal glia to glutamate
In addition to assaying cell number, the effect of glutamate on the corporation of bromodeoxyuridine (BrdU) into the nuclei of the glial cells was determined. BrdU, an analog of the nucleotide thymidine, is incorporated into replicating DNA and can be detected by immunocytochemistry using an anti-BrdU monoclonal antibody. In five experiments, cultures of human retinal glial cells were exposed for two days in a serum-free medium (see Materials and Methods) supplemented with 10 /xM BrdU and with or without 1 mM glutamate. Exposure to glutamate was associated with a significantly (P < 0.001, Student's t-test) higher percent of nuclei that were immunoreactive for BrdU. Specifically, immunocytochemistry revealed that 22% (S.D. = 5) of the glial cells in the control plates had nuclei positive for BrdU, while 68% (S.D. = 5) of the nuclei in the glutamate-treated group stained positively. These experiments demonstrated that glutamate is a mitogen for the human retinal glial cells in our culture system. The effect of the duration of exposure to glutamate on retinal glial cell proliferation was also assessed. This was of interest, since cells often require a number of hours of exposure to mitogens in order for proliferation to occur 9. In Fig. 4 , glial cultures were exposed to a serum-free medium supplemented with 1 mM glutamate. At various times, some cultures were switched to medium B without added glutamate. All cultures were assayed for a change in cell number at 48 h. Exposure to an elevated concentration of glutamate for 3 h or less did not significantly (P > 0.2, Student's t-test) affect cell proliferation. However, at least 4 h of exposure did significantly increase (P < 0.05, Student's ttest) the proliferation of retinal glial cells. Thus, a period of several hours of exposure to elevated glutamate concentrations is required to induce mitogenesis in these cells under the conditions used here. 
Pharmacology of the mitogenic effect of glutamate
With the finding that glutamate is a glial mitogen, it was of interest to study the mechanism by which glutamate-exposure stimulates proliferation. An initial question was what subtype of glutamate receptor is involved in this response. To address this question, the effects on glutamate-induced proliferation of D-2-amino-5-phosphonovalerate (D-AP5, a competitive NMDA antagonist), MK-801 (a non-competitive NMDA antagonist) and CNQX (a blocker of non-NMDA glutamate receptors) were assessed (Figs. 5-7 ). D-AP5 (Fig. 5 ) and MK-801 (Fig. 6 ) inhibited significantly (P < 0.005, Student's t-test, at 100/~M and 1 /~M concentrations, respectively) the proliferative effect of glutamate. In contrast to the NMDA-antagonists, 20/~M CNQX did not affect (P > 0.2, Student's t-test) the mitogenic response of the glial cells to glutamate (Fig. 7) . These pharmacological experiments point to a role for the NMDA subtype of glutamate receptor in mediating the proliferative response of retinal glial cells to glutamate.
Consistent with a role for NMDA receptors, Other glutamate agonists were also tested for their effects on glial proliferation. We found that kainate (100/xM) and quisqualate (50/~M) induced proliferative responses (Fig. 9) . We then asked whether kainate or quisqualate acted at non-NMDA or NMDA receptors to stimulate proliferation in our glial cell cultures. duced mitogenic effects observed in this study occurred by activation of NMDA receptors. To obtain further evidence supporting a role for NMDA channels in mediating a mitogenic response, the effect of extracellular magnesium on NMDA-induced proliferation was assessed. The effect of magnesium was of interest, since this divalent cation blocks NMDA, but not non-NMDA, channels 3. Table II shows that raising the concentration of magnesium in the medium to 10 mM significantly (P < 0.01, Student's t-test) inhibited the proliferative effect of 500 gM NMDA.
A requirement of the glial NMDA receptor channels for glycine was not systematically assessed. Although the media used in the experiments summarized in Table II did not contain added glycine (Table I) (Table II) . It is known from studies of other cells 3 that sodium and calcium can enter a cell via NMDA channels. As shown in Table II , a nominally sodium-free medium did not significantly (P = 0.21, Student's t-test) affect the induction of proliferation by 500 /xM NMDA. In contrast, a low cal- cium concentration in the medium prevented the mitogenic effect of 500 ~M NMDA (Table II) . These findings support the possibility that an influx of cal-
TABLE II
Effect of extracellular concentrations of magnesium, sodium and calcium on the NMDA-induced proliferation of human retinal glial cells in culture
Cells were exposed to either medium C, which contained 1 mM Mg 2+, or its variations (see Table I ) without or with 500 p.M NMDA. After 4.5 h, the cultures were switched to medium B. The cell proliferation assay was completed 2 days later. Each value represents the mean (_+ S.D.) of at least four experiments.
Conditions Increase in cell number (%)
No NMDA, 1 mM Mg 2+ 9+4 NMDA, 1 mM Mg 2+ 28+7 NMDA, 10 mM Ng 2+ 8+4 NMDA, low Na ÷ 23 5:3 NMDA, low Ca 2+ 6+6 cium plays a role in the proliferative response of human retinal glial cells to NMDA.
DISCUSSION
The results show that glutamate, via activation of NMDA receptors, stimulates the proliferation of human retinal glial cells in culture. Our evidence for a role of NMDA receptors is based on a number ef findings. Importantly, the glutamate-induced proliferation is blocked by I>AP5 and MK-801 (antagonists of NMDA receptors), but not by CNQX (an antagonist of non-NMDA glutamate receptors). Also, NMDA itself stimulates proliferation of retinal glial cells. Furthermore, the effect of NMDA on cell proliferation is sensitive to elevated magnesium levels and is dependent on extracellular calcium. These characteristics are consistent with an activation of NMDA receptor channels 3.
This is the first report showing evidence for the presence of functional NMDA receptors on glial cells. Consistent with the concept that at least some glia have NMDA receptors are recent studies using antibodies to cDNA-derived peptides of an NMDA receptor 26 or in situ hybridization with riboprobes directed against the NMDAR1 subunit of the receptor ~5. These reports indicate that hippocampal astrocytes 26 and cerebellar Bergmann glia 15 express NMDA receptors. In contrast, functional NMDA receptor channels have not been detected in studies of cultured glia from perinatal rodent and avian brains 7"~°'1~, Mfiller glial cells freshly dissociated from the salamander retina 12' 32 and astrocytes on the inner surface of the rabbit retina ~4. Whether a difference in the detection of NMDA receptor channels in glia reflects differences in species, degree of maturation, CNS sites, types of glial cells, enzyme-treatment of cells, in vitro conditions or assay techniques is not known.
It is clear that caution concerning changes in cellular characteristics in culture is needed. However, the culture system used here appears to be a reasonable system in which to study aspects of the pathophysiology of human retinal glial cells. For example, the cells in our cultures are immunoreactive to antibodies for glial fibrillary acidic protein and Miiller cells 3°, as are proliferating cells often found in multicellular complexes located on and under the retinal surface or extending into the vitreous in eyes with various retinal diseases ~3'~7'3~. Yet, despite these similarities, it remains to be demonstrated that the NMDA receptors found in our cultured cells are, in fact, also expressed by retinal glial cells in vivo.
The NMDA receptors on cultured retinal glial cells may differ from those found on neurons. One possible difference may be in the sensitivity of the NMDA channel to blockade by magnesium. Neural NMDA channels at the resting membrane potential are blocked significantly by physiological concentrations of magnesium 3. In contrast, the effectiveness of NMDA on glial proliferation in the presence of 1 to 1.5 mM Mg 2+ ( Fig. 8 and Table II ) suggests a relatively low sensitivity to the blocking action of this divalent cation. Perhaps retinal glia express heteromeric NMDA receptor channels which have a low sensitivity to magnesium-block as has been found.in recent molecular studies 18' 22~23. Future electrophysiological recordings are needed to characterize the magnesium sensitivity of the NMDA channels in human retinal glial cells. Another possible difference between glial and neuronal NMDA receptors may be the effectiveness of various ligands. For example, we found that 100 ~M kainate was only slightly less effective than 100 ~M NMDA at inducing glia proliferation (Figs. 8 and 9 ). The proliferation induced by kainate involved the activation of NMDA receptors, since MK-801 and not CNQX, was inhibitory (Fig. 9 ). This effectiveness of kainate at gIial NMDA receptors appears to be greater than its effectiveness at the NMDAR1 subtype of NMDA receptor channel 24. However, the binding of kinate to other subtypes of NMDA receptor channels has not been reported. Our finding that kainate activates NMDA receptors on retinal glial cells is consistent with in vivo experiments in which Sahel et al. 3~ found that intravitreal injection of kainate induced mitoses in retinal Miiller cells by a mechanism inhibited by ketamine, a non-competitive NMDA-blocker. We also observed that a relatively high concentration of glutamate (Fig. 3 ) was needed to induce proliferation. Rather than indicating a low sensitivity of the glial NMDA receptor to glutamate, we speculate that an active uptake carrier in the glia lowers the glutamate concentration during the 4-h period required to induce a mitogenic response. Use of the patch clamp technique to study the effects of glutamate and its agonists on NMDA receptor channels of retinal glial cells should help clarify these issues. Also, subsequent studies are needed to characterize the effects on glial NMDA receptor channels of glycine and other modulators.
The mechanism by which activation of NMDA receptors on retinal glial cells induces a mitogenic response is uncertain. Our experiments indicate that an influx of calcium is required for the NMDA-induced proliferation. However, the subsequent pathway by which the NMDA receptor signal is processed is not known. In brain cells, activation of NMDA receptors can be associated with phosphorylation of tyrosine residues in a protein kinase 5 and stimulation of the inositol phosphate/diacylglycerol second messenger pathway 33. Whether these pathways play a role in the proliferative response to NMDA studied here remains to be determined.
Glutamate is not the only neurotransmitter that can be a glial mitogen. The acetylcholine analog, carbachol, stimulates DNA synthesis in cultured astrocytes from the perinatal rodent brain 4. However, this is an age-dependent phenomenon with minimal stimulation of DNA synthesis in glia from rats older than 2 weeks postnatal. We assayed for the mitogenic effect of carbachol in our cultures of glia from the adult retina and did not detect any effect (unpublished observations). The study presented here is the first report of a neurotransmitter being mitogenic for glia from the adult nervous system.
What could be the significance of NMDA receptors on retinal glial cells? Since most retinal neurons are glutamatergic 2~, NMDA receptors are likely to be activated in the retina. Thus, glutamate may act as a neuron-to-glial signal as well as a transmitter for communication between retinal neurons. However, the physiological function of a short-term activation of NMDA receptors on retinal glia is unknown. Perhaps an influx of calcium via NMDA channels may activate the calcium-sensitive potassium channels that are present in these cells 27 and, thereby facilitate in the regulation of potassium homeostasis in the retina.
Another possible function of glial NMDA receptors in the retina may be to mediate a cellular response to pathophysiological conditions, such as retinal ischemia, trauma or detachment, in which neurons are injured. Under these conditions there may be a prolonged elevation of extracellular glutamate released by depolarized neurons. Our proliferation assays demonstrate that the exposure of retinal glial cells to glutamate for several hours elicits a mitogenic response via activation of NMDA receptors. A glutamate-induced proliferation of glia may be a successful adaptive response of the retina resulting in the creation of more glial cells that would reduce potentially neurotoxic levels of glutamate. On the other hand, an excessive proliferation of glial cells often is a significant factor in compromising neural function with disease or injury. It remains to be determined whether drugs which block NMDA receptors may be useful in limiting detrimental effects of glial proliferation in the retina.
